MetaVia Inc. (MTVA) - Dilution Analysis

10-Q filing | 4.9M shares outstanding

POS AM filing: This prospectus relates to the offer and resale from time to time of up to 936,846 shares of our common stock

10-K filing | 5.1M shares outstanding

8-K filing: MetaVia Inc. completed a public offering of Class A and Class B Units, with each unit consisting of common stock or pre-funded warrants and common stock warrants, resulting in net proceeds of approximately $7.7 million. ($7.7M proceeds)

S-1/A filing: This S-1/A filing from 2026-01-12 relates to an offering of Class A Units and Class B Units, as well as shares of common stock issuable upon exercise of pre-funded warrants and Common Warrants.

S-1 filing: An S-1 filing indicating an intention to register shares for issuance related to stock options, warrants, restricted stock units, and a potential future issuance pursuant to equity incentive plans.

8-K filing: Stock split 1-for-11 | Outstanding: 24,415,876 → 2,300,000

10-Q filing | 24.4M shares outstanding

10-Q filing | 24.2M shares outstanding

S-3 filing: S-3 filing for the offer and resale of up to 14,084,507 shares of common stock by selling securityholders.

8-K filing: MetaVia Inc. completed a private placement on May 14, 2025, issuing 9,479,345 shares of common stock at $0.71 per share and 4,605,162 pre-funded common stock purchase warrants at $0.709 per warrant, raising gross proceeds of approximately $10.0 million. ($9.98M proceeds)

10-Q filing | 19.6M shares outstanding

8-K filing: On April 15, 2025, Pre-Funded Warrants to purchase 1,430,000 shares of MetaVia Inc.'s common stock were exercised, resulting in a total of 10,084,869 shares of Common Stock issued and outstanding.

POS AM filing: This prospectus relates to the offering of up to 16,824,408 shares of common stock by selling securityholders.

10-K filing | 8.7M shares outstanding

10-Q filing | 8.6M shares outstanding

10-Q filing | 8.2M shares outstanding

S-1 filing: This S-1 filing registers the resale of up to 17,175,579 shares of common stock by selling securityholders.

8-K filing: NeuroBo Pharmaceuticals, Inc. entered into agreements for a registered direct offering of 763,359 shares at $3.93 per share and a private placement of 4,325,701 shares (or pre-funded warrants) and warrants, with gross proceeds of approximately $3 million and $17 million, respectively, for working capital and general corporate purposes. ($20.0M proceeds)

10-Q filing | 5.1M shares outstanding

S-3 filing: NeuroBo Pharmaceuticals, Inc. files an S-3 registration statement to offer and sell up to $150,000,000 of any combination of common stock, preferred stock, and debt securities from time to time.

10-K filing | 5.1M shares outstanding

8-K filing: Stock split 1-for-8 | Outstanding: 40,606,537 → 5,075,817

10-Q filing | 40.6M shares outstanding

10-Q filing | 40.5M shares outstanding

10-Q filing | 27.2M shares outstanding

10-K filing | 0.9M shares outstanding

S-3 filing: This S-3 filing relates to the resale of up to 22,629,907 shares of common stock by selling stockholders, including shares underlying warrants.

10-Q filing | 0.9M shares outstanding

8-K filing: NeuroBo Pharmaceuticals, Inc. closed a public offering on November 8, 2022, issuing 3,147,003 shares of common stock (including 750,000 shares from the Overallotment Option), 2,602,997 shares of Series B Preferred Stock, and warrants to purchase 11,500,000 shares of common stock for net proceeds of approximately $15.1 million; also closed a private placement with Dong-A, issuing $22 million of Series A Convertible Preferred Stock and additional Series A Convertible Preferred Stock and warrants for $15 million in gross proceeds.

S-1/A filing: S-1/A filing discussing common and preferred stock rights, including details of a private offering of Series A Convertible Preferred Stock to Dong-A contingent upon a Qualified Financing.

S-1/A filing: The filing discusses the rights and preferences of common and preferred stock, including voting rights, dividend entitlements, and liquidation rights. It also details a private offering of Series A Convertible Preferred Stock to Dong-A, contingent upon a Qualified Financing and stockholder approval.

S-1 filing: The filing discusses common and preferred stock rights and details a private offering of Series A Convertible Preferred Stock and warrants to Dong-A concurrently with a qualified financing.

8-K filing: Stock split 1-for-30 | Outstanding: 26,661,771 → 888,636

10-Q filing | 26.7M shares outstanding

10-Q filing | 26.7M shares outstanding

10-K filing | 19.7M shares outstanding

10-Q filing | 22.3M shares outstanding

8-K filing: NeuroBo Pharmaceuticals, Inc. completed a registered direct offering of 4,307,693 shares of common stock at $3.25 per share, and a concurrent private placement of warrants to purchase up to 4,307,693 shares of common stock at an exercise price of $3.75 per share. ($14.0M proceeds)

10-Q filing | 22.3M shares outstanding

10-Q filing | 22.2M shares outstanding

S-3 filing: The filing is an S-3 shelf registration for the potential offering of up to $150,000,000 in aggregate amount of common stock, preferred stock, and/or debt securities.

S-3 filing: This prospectus relates to the resale from time to time of up to 3,243,875 shares of common stock of NeuroBo Pharmaceuticals, Inc. by the Selling Stockholders.

10-K filing | 22.2M shares outstanding

S-3 filing: This prospectus relates to the resale from time to time of up to 5,000,000 shares of common stock of NeuroBo Pharmaceuticals, Inc. by the Selling Stockholders.

8-K filing: NeuroBo Pharmaceuticals, Inc. completed a private placement on January 21, 2021, issuing 2,500,000 shares of common stock at $4.00 per share and warrants to purchase 2,500,000 shares, resulting in gross proceeds of $10.0 million. ($10.0M proceeds)

8-K filing: NeuroBo Pharmaceuticals acquired ANA Therapeutics on December 31, 2020, issuing 3,243,875 shares of common stock to ANA stockholders as part of the merger consideration.

10-Q filing | 16.4M shares outstanding

10-Q filing | 16.4M shares outstanding

10-Q filing | 16.4M shares outstanding

10-K filing | 15.7M shares outstanding